| Literature DB >> 26818255 |
Yan-Song Qi1, Hai-Jun Wang1, Shao-Jie Wang1, Zheng-Zheng Zhang1, Ai-Bing Huang1, Jia-Kuo Yu2.
Abstract
BACKGROUND: Posterior Cruciate Ligament (PCL) ruptures are common sports injuries. One of the key controversies in PCL reconstruction is whether double-bundle reconstruction provides biomechanical and clinical outcomes superior to single-bundle reconstruction.Entities:
Mesh:
Year: 2016 PMID: 26818255 PMCID: PMC4730768 DOI: 10.1186/s12891-016-0896-z
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
PRISMA checklist
| Section/Topic | # | Checklist item | Reported on page# |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3-4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design. | 4 |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed [e.g., Web address], and, if available, provide registration information including registration number. | |
| Eligibility criteria | 6 | Specify study characteristics [e.g., PICOS, length of follow-up] and report characteristics [e.g., years considered, language, publication status] used as criteria for eligibility, giving rationale. | 4 |
| Information sources | 7 | Describe all information sources [e.g., databases with dates of coverage, contact with study authors to identify additional studies] in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4 |
| Study selection | 9 | State the process for selecting studies [i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis]. | 4-5 and Figure |
| Data collection process | 10 | Describe method of data extraction from reports [e.g., piloted forms, independently, in duplicate] and any processes for obtaining and confirming data from investigators. | 4-5 |
| Data items | 11 | List and define all variables for which data were sought [e.g., PICOS, funding sources] and any assumptions and simplifications made. | 4,18 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies [including specification of whether this was done at the study or outcome level], and how this information is to be used in any data synthesis. | |
| Summary measures | 13 | State the principal summary measures [e.g., risk ratio, difference in means]. | |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency [e.g., I2] for each meta-analysis. | 4-5 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence [e.g., publication bias, selective reporting]. | |
| Additional analyses | 16 | Describe methods of additional analyses [e.g., sensitivity or subgroup analyses, meta-regression]. | |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 4-5 and Figure |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted [e.g., study size, PICOS, follow-up period] and provide the citations. | 5-12 |
| 19-24 | |||
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment [see item 12]. | |
| Results of individual studies | 20 | For all outcomes considered [benefits or harms], present, for each study: [a] simple summary data for each intervention group [b] effect estimates and confidence intervals, ideally with a forest plot. | 25-26 |
| Table | |||
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies [see Item 15]. | |
| Additional analysis | 23 | Give results of additional analyses, if done [e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]]. | |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups [e.g., healthcare providers, users, and policy makers]. | 13-16 |
| Limitations | 25 | Discuss limitations at study and outcome level [e.g., risk of bias], and at review-level [e.g., incomplete retrieval of identified research, reporting bias]. | 16-17 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 17 |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support; role of funders for the systematic review. | 18 |
Fig. 1Literatures screening process
Clinical study features
| Study | Publication year | Type of study | Level of evidence |
|---|---|---|---|
| Wang et al. [ | 2004 | Prospectively randomized study | II |
| Houe et al. [ | 2004 | Retrospective comparative study | III |
| Fanelli et al. [ | 2008 | Retrospective comparative study | V |
| Kim et al. [ | 2009 | Retrospective comparative study | III |
| Shon OJ et al. [ | 2010 | Retrospective comparative study | III |
| Yoon et al. [ | 2011 | Randomized controlled study | II |
| Fanelli et al. [ | 2012 | Retrospective comparative study | V |
| Li et al. [ | 2014 | Lesser-quality randomized controlled study | II |
Characteristics of the included clinical studies
| Study | No. of patients (S/D) | Graft choice(S/D) | Follow-up (mo) (S/D) |
|---|---|---|---|
| Wang et al. [ | 35(19/16) | Semitendinosus and gracilis | 41.0/28.2 |
| Houe et al. [ | 16(6/10) | Patellar tendon autograft/semitendinosus and gracilis autograft | 31 |
| Fanelli et al. [ | 90(45/45) | Achilles tendon and tibialis anterior allograft | ≥24 |
| Kim et al. [ | 29(G1: 8/ G2: 11/G3:10) | Achilles tendon allograft | 32.4/31.9/33.6 |
| Shon OJ et al. [ | 30(14/16) | Bone-patellar tendon-bone (BPTB) allograft and achilles tendon allograft/achilles tendon allograft | 34/36 |
| Yoon et al. [ | 53(25/28) | Achilles tendon allograft | 28.5/27.4 |
| Fanelli et al. [ | 90(45/45) | Achilles tendon and tibialis anterior allograft | ≥24 |
| Li et al. [ | 46(22/24) | Tibialis anterior allograft | 25.1/23.5 |
S single bundle group, D double bundle group, G1 group 1, single bundle, transtibial, G2 group 2, single bundle, transtibial inlay technology, G3 group 3, double bundle, transtibial inlay technology